Skip to content

COMPARISON OF INTRAVENOUS LABETALOL AND HYDRALAZINE FOR THE CONTROL OF SEVERE HYPERTENSION IN PREGNANCY: A RANDOMIZED CONTROLLED TRIAL

COMPARISON OF INTRAVENOUS LABETALOL AND HYDRALAZINE FOR THE CONTROL OF SEVERE HYPERTENSION IN PREGNANCY: A RANDOMIZED CONTROLLED TRIAL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
PACTR
Registry ID
PACTR202010738538062
Enrollment
120
Registered
2020-10-01
Start date
2018-10-14
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe hypertension in pregnancy Cardiology

Interventions

Sponsors

MUHAMMAD Sagir
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: • Consenting pregnant women with severe hypertension in pregnancy with systolic blood pressure (SBP) of at least 160 mmHg and/or diastolic blood pressure (DBP) of at least 110 mmHg. • Gestational age of 28 weeks or more which will be determined based on ultrasound scan or last menstrual period. • Live singleton fetus with normal fetal heart rate.

Exclusion criteria

Exclusion criteria: • All women with cardiac disease such as heart block, ischaemic heart disease, and hypertensive cardiac disease. • Asthma • History of allergy to either hydralazine or labetalol. • Chronic medical disorder such as chronic kidney disease and diabetes mellitus. • Women with haemoglobinopathy such as HbSS. • Multiple gestation. • Preterm labour at gestational age of less than 34 weeks • Women who are already on other antihypertensive drugs. • Patients with stroke • Unconscious patients • Patients with HELLP syndrome and liver disease • Presence of fetal distress • Non consenting women

Design outcomes

Primary

MeasureTime frame
Mean reduction in Mean Arterial Blood Pressure and rate of Persistent hypertension

Secondary

MeasureTime frame
Perinatal outcome and maternal sideeffects

Countries

Nigeria

Contacts

Public ContactSAGIR MUHAMMAD

DEPARTMENT OF OBS AND GYNAE SPECIALIST HOSPITAL GOMBE

sagirmuhammad2013@gmail.com+2348034309414

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026